Issue 2 Anticoagulation Matters:
Medical Prophylaxis Edition

Exciting medical research breakthroughs and tips for VTE management, risk assessment and prevention.

A/Prof. Hitos: Exciting Medical Research Breakthroughs in Australia

 

A/Prof. Hitos: Steps to a Multifaceted Approach to VTE Prevention in Hospitals

 

 Prof. Ward: Improving Rates of VTE Risk Assessment for Medical Patients

 

LMWH: low molecular weight heparin VTE = venous thromboembolism.

References

1 Clexane Australian Product Information, 13 July 2018.
2 Fareed J et al. Semin Thromb Hemost 2004;30:706–13.

Date of preparation: August 2019. SM_SAN980. SAANZ.ENO.19.01.0069c

*Clexane Safety Lock as an automatic safety lock system.

Further information is available on request from Sanofi.

Clexane

PBS Information: CLEXANE®. General Benefit Antithrombotic agent. Refer to PBS schedule for full information.CLEXANE® with Automatic Safety Lock System. Refer to PBS schedule for full information. CLEXANE® FORTE. This product is not listed on the PBS.

Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.


sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.

Clexane Safety Lock Webinars

VTEMATTERS.COM.AU

Your patients' information portal for all VTE matters

Password: support

Receive future issues of Anticoagulation Matters, curated specifically for you.

 

Access patient information and resources on VTE and Clexane®.